Cytokines as regulators of proliferation and survival of healthy and malignant peripheral B cells

Cytokine

Volumn 60, Issue 1, 2012, Pages 13-22

  Cohen, Sivan ^a   Shachar, Idit ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

APRIL; BAFF; Cytokines; HGF; Midkine; MIF; Peripheral b cell; Survival

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; CD74 ANTIGEN; CYTOKINE; HERMES ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MIDKINE; PROTEIN BCL 2; SCATTER FACTOR; TUMOR NECROSIS FACTOR;

APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BREAST CANCER; CANCER INVASION; CANCER PROGNOSIS; CARCINOGENESIS; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HODGKIN DISEASE; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

B-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; HOMEOSTASIS; HUMANS; MODELS, IMMUNOLOGICAL; RECEPTORS, CYTOKINE; SPLEEN;

EID: 84865409702     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.019     Document Type: Review

References (184)

1. Loder B.F., Mutschler B., Ray R.J., Paige C.J., Sideras P., Torres R., et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999, 190:75.
2. Monroe JG, Dorshkind K. Fate decisions regulating bone marrow and peripheral B lymphocyte development. Elsevier; 2007. p. 1-50.
3. Kraus M., Alimzhanov M.B., Rajewsky N., Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 2004, 117:787-800.
4. Balkwill F. Tumour necrosis factor. Br Med Bull 1989, 45:389.
5. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959.
6. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
7. Berg D., Lehne M., Müller N., Siegmund D., Münkel S., Sebald W., et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007, 14:2021-2034.
8. Siegel R.M., Muppidi J.R., Sarker M., Lobito A., Jen M., Martin D., et al. SPOTS. J Cell Biol 2004, 167:735-744.
9. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111.
10. Mackay F., Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
11. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
12. Hahne M., Kataoka T., Schröter M., Hofmann K., Irmler M., Bodmer J.L., et al. A new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998, 188:1185-1190.
13. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
14. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005, 17:282-289.
15. Mackay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502.
16. Moisini I., Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009, 158:155-163.
17. Ng L.G., Mackay C.R., Mackay F. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 2005, 42:763-772.
18. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
19. Mackay F., Sierro F., Grey S., Gordon T. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Direct Autoimmun 2005, 8:243-265.
20. Mackay F., Silveira P.A., Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007, 19:327-336.
21. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
22. Do R.K.G., Hatada E., Lee H., Tourigny M.R., Hilbert D., Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000, 192:953-964.
23. Hsu B.L., Harless S.M., Lindsley R.C., Hilbert D.M., Cancro M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002, 168:5993.
24. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
25. Claudio E., Brown K., Park S., Wang H., Siebenlist U. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat Immunol 2002, 3:958-965.
26. Khan WN, Shinners NP, Castro I, Hoek KL. BAFF receptor regulation of peripheral B-lymphocyte survival and development. BLyS Ligands and Receptors; 2010. p. 19-41.
27. Hildebrand JM, Xie P, Bishop GA. Signal transduction by receptors for BAFF and APRIL. BLyS Ligands and Receptors; 2010. p. 93-114.
28. Woodland R.T., Fox C.J., Schmidt M.R., Hammerman P.S., Opferman J.T., Korsmeyer S.J., et al. Multiple signaling pathways promote B lymphocyte stimulator-dependent B-cell growth and survival. Blood 2008, 111:750-760.
29. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 2002, 17:515-524.
30. Sasaki Y., Derudder E., Hobeika E., Pelanda R., Reth M., Rajewsky K., et al. Canonical NF-κB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006, 24:729-739.
31. Mackay F., Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008, 19:263-276.
32. Stadanlick J.E., Kaileh M., Karnell F.G., Scholz J.L., Miller J.P., Quinn W.J., et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat Immunol 2008, 9:1379-1387.
33. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453.
34. Hatada E.N., Do R.K.G., Orlofsky A., Liou H.C., Prystowsky M., MacLennan I., et al. NF-κB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-κB2 p100 to p52 in quiescent mature B cells. J Immunol 2003, 171:761.
35. Enzler T., Bonizzi G., Silverman G.J., Otero D.C., Widhopf G.F., Anzelon-Mills A., et al. Alternative and classical NF-[kappa] B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25:403-415.
36. Mackay F., Figgett W.A., Saulep D., Lepage M., Hibbs M.L. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010, 237:205-225.
37. Bossen C., Cachero T.G., Tardivel A., Ingold K., Willen L., Dobles M., et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012.
38. Patke A., Mecklenbräuker I., Erdjument-Bromage H., Tempst P., Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKCβ-and Akt-dependent mechanism. J Exp Med 2006, 203:2551.
39. Craxton A., Draves K.E., Gruppi A., Clark E.A. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005, 202:1363.
40. Mecklenbräuker I., Kalled S.L., Leitges M., Mackay F., Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCδ-mediated nuclear signalling. Nature 2004, 431:456-461.
41. Xu L.G., Wu M., Hu J., Zhai Z., Shu H.B. Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 2002, 72:410-416.
42. White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev 2003, 17:1813.
43. Fox C.J., Hammerman P.S., Cinalli R.M., Master S.R., Chodosh L.A., Thompson C.B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003, 17:1841-1854.
44. Moreno C., Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008, 22:211-219.
45. Castigli E., Scott S., Dedeoglu F., Bryce P., Jabara H., Bhan A.K., et al. Impaired IgA class switching in APRIL-deficient mice. Proc Nat Acad Sci USA 2004, 101:3903.
46. Varfolomeev E., Kischkel F., Martin F., Seshasayee D., Wang H., Lawrence D., et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004, 24:997.
47. Planelles L., Carvalho-Pinto C.E., Hardenberg G., Smaniotto S., Savino W., Gómez-Caro R., et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004, 6:399-408.
48. Yu G., Boone T., Delaney J., Hawkins N., Kelley M., Ramakrishnan M., et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000, 1:252-256.
49. O'Connor B.P., Raman V.S., Erickson L.D., Cook W.J., Weaver L.K., Ahonen C., et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91.
50. Novak A.J., Bram R.J., Kay N.E., Jelinek D.F. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002, 100:2973-2979.
51. Kern C., Cornuel J.F., Billard C., Tang R., Rouillard D., Stenou V., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004, 103:679-688.
52. Novak A.J., Grote D.M., Stenson M., Ziesmer S.C., Witzig T.E., Habermann T.M., et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004, 104:2247.
53. Moreaux J., Legouffe E., Jourdan E., Quittet P., Rème T., Lugagne C., et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004, 103:3148-3157.
54. He B., Chadburn A., Jou E., Schattner E.J., Knowles D.M., Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004, 172:3268.
55. Endo T., Nishio M., Enzler T., Cottam H.B., Fukuda T., James D.F., et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway. Blood 2007, 109:703-710.
56. Briones J., Timmerman J.M., Hilbert D.M., Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002, 30:135-141.
57. Novak A.J., Darce J.R., Arendt B.K., Harder B., Henderson K., Kindsvogel W., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103:689-694.
58. Elsawa S.F., Novak A.J., Grote D.M., Ziesmer S.C., Witzig T.E., Kyle R.A., et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood 2006, 107:2882.
59. Amanna I.J., Clise-Dwyer K., Nashold F.E., Hoag K.A., Hayes C.E. Cutting edge: A/WySnJ transitional B cells overexpress the chromosome 15 proapoptotic Blk gene and succumb to premature apoptosis. J Immunol 2001, 167:6069.
60. Nishio M., Endo T., Tsukada N., Ohata J., Kitada S., Reed J.C., et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 2005, 106:1012-1020.
61. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
62. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of " nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
63. Vincent F.B., Morand E.F., Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol 2012, 90:293-303.
64. Rossi J.F., Moreaux J., Hose D., Requirand G., Rose M., Rouille V., et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study. Br J Cancer 2009, 101:1051-1058.
65. Ansell S.M., Witzig T.E., Inwards D.J., Porrata L.F., Ythier A., Ferrande L., et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008, 14:1105-1110.
66. Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003, 149:1-38.
67. Kishimoto T. The biology of interleukin-6. Blood 1989, 74:1-10.
68. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
69. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990, 8:253-278.
70. van Kooten C., Rensink I., Aarden L., van Oers R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993, 7:618-624.
71. Barton B.E. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 2005, 9:737-752.
72. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
73. George M., Vaughn J.H. In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med 1962, 111:514-521.
74. Bloom B.R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80.
75. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Nat Acad Sci USA 1966, 56:72.
76. Sun H.W., Bernhagen J., Bucala R., Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Nat Acad Sci 1996, 93:5191.
77. Sun H.W., Swope M., Craig C., Bedarkar S., Bernhagen J., Bucala R., et al. The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng 1996, 9:631-635.
78. Conroy H., Mawhinney L., Donnelly S. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 2010, 103:831-836.
79. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000, 20:751-762.
80. Calandra T. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor 1994, 1895-1902.
81. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis; 1999. p. 341-6.
82. Mitchell R.A., Liao H., Chesney J., Fingerle-Rowson G., Baugh J., David J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002, 99:345-350.
83. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Nat Acad Sci 1996, 93:7849.
84. Bernhagen J., Bacher M., Calandra T., Metz C.N., Doty S.B., Donnelly T., et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 1996, 183:277-282.
85. Meyer-Siegler K., Hudson P.B. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996, 48:448-452.
86. Bando H., Matsumoto G., Bando M., Muta M., Ogawa T., Funata N., et al. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 2002, 93:389-396.
87. Nishihira J., Ishibashi T., Fukushima T., Sun B., Sato Y., Todo S. Macrophage migration inhibitory factor (MIF): its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci 2003, 995:171-182.
88. Chesney J., Metz C., Bacher M., Peng T., Meinhardt A., Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999, 5:181-191.
89. Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003, 197:1467.
90. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13:587-596.
91. Schwartz V., Kruttgen A., Weis J., Weber C., Ostendorf T., Lue H., et al. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur J Cell Biol 2012, 91:435-449.
92. Stumptner-Cuvelette P., Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta 2002, 1542:1.
93. Naujokas M.F., Morin M., Anderson M.S., Peterson M., Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993, 74:257-268.
94. Maharshak N., Cohen S., Lantner F., Hart G., Leng L., Bucala R., et al. CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol 2010, 16:3258.
95. Gore Y., Starlets D., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008, 283:2784-2792.
96. Shi X., Leng L., Wang T., Wang W., Du X., Li J., et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006, 25:595-606.
97. Shachar I., Flavell R.A. Requirement for invariant chain in B cell maturation and function. Science 1996, 274:106.
98. Matza D., Kerem A., Lantner F., Shachar I. Invariant chain induced B cell differentiation requires intramembrane - proteolytic release of the cytosolic domain. Immunity 2002, 17:549-560.
99. Matza D., Kerem A., Shachar I. Invariant chain, a chain of command. Trends Immunol 2003, 24:264-268.
100. Matza D., Wolstein O., Dikstein R., Shachar I. Invariant chain induces B cell maturation by activating a TAFII105-NF-κB-dependent transcription program. J Biol Chem 2001, 276:27203-27206.
101. Starlets D., Gore Y., Binsky I., Haran M., Harpaz N., Shvidel L., et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006, 107:4807-4816.
102. Calvi L., Adams G., Weibrecht K., Weber J., Olson D., Knight M., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
103. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
104. Tokoyoda K., Egawa T., Sugiyama T., Choi B., Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004, 20:707-718.
105. Sapoznikov A., Pewzner-Jung Y., Kalchenko V., Krauthgamer R., Shachar I., Jung S. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat Immunol 2008, 9:388-395.
106. Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, et al. IL-8 secreted in a macrophage migration-inhibitory factor-and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. National Acad Sciences; 2007. p. 13408.
107. Dios A., Mitchell R.A., Aljabari B., Lubetsky J., O'Connor K., Liao H., et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 2002, 45:2410-2416.
108. Harada A., Sekido N., Akahoshi T., Wada T., Mukaida N., Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994, 56:559-564.
109. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
110. Smyth M.J., Zachariae C.O., Norihisa Y., Ortaldo J.R., Hishinuma A., Matsushima K. IL-8 gene expression and production in human peripheral blood lymphocyte subsets. J Immunol 1991, 146:3815-3823.
111. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology 2005, 7:122-133.
112. Binsky I., Lantner F., Grabovsky V., Harpaz N., Shvidel L., Berrebi A., et al. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol 2010, 184:4761.
113. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242.
114. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor; 1989.
115. Nakamura T., Nawa K., Ichihara A., Kaise N., Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987, 224:311-316.
116. Naka D., Ishii T., Yoshiyama Y., Miyazawa K., Hara H., Hishida T., et al. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem 1992, 267:20114-20119.
117. Shimomura T., Miyazawa K., Komiyama Y., Hiraoka H., Naka D., Morimoto Y., et al. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem 1995, 229:257-261.
118. Naldini L., Vigna E., Narsimhan R., Gaudino G., Zarnegar R., Michalopoulos G., et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991, 6:501.
119. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771.
120. Uehara Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T., et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995, 373:702-705.
121. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M.L., Kmiecik T.E., Vande Woude G.F. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802.
122. Rubin J.S., Bottaro D.P., Aaronson S.A. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta 1993, 1155:357.
123. van der Voort R., Ei Taher T., Derksen P.W.B., Spaargaren M., van der Neut R., Pals S.T. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000, 79:39-90.
124. Giordano S., Zhen Z., Medico E., Gaudino G., Galimi F., Comoglio P. Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Nat Acad Sci 1993, 90:649.
125. Comoglio P.M. Pathway specificity for Met signalling. Nat Cell Biol 2001, 3:161-162.
126. Kosai K., Matsumoto K., Nagata S., Tsujimoto Y., Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 1998, 244:683-690.
127. Yamamoto K., Morishita R., Hayashi S., Matsushita H., Nakagami H., Moriguchi A., et al. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 2001, 37:1341-1348.
128. Nakamura T., Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B: Phys Biol Sci 2010, 86:588.
129. van der Voort R., Taher T.E.I., Wielenga V.J.M., Spaargaren M., Prevo R., Smit L., et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 1999, 274:6499.
130. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002, 16:3074.
131. Gordin M., Tesio M., Cohen S., Gore Y., Lantner F., Leng L., et al. C-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol 2010, 185:2020.
132. van der Voort R., Taher T.E., Derksen P.W., Spaargaren M., van der Neut R., Pals S.T. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000, 79:39-90.
133. Birchmeier C., Birchmeier W., Gherardi E., Woude G.F.V. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
134. Hurle R, Davies G, Parr C, Mason M, Jenkins S, Kynaston H, et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review; 2005.
135. Jücker M., Günther A., Gradl G., Fonatsch C., Krueger G., Diehl V., et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 1994, 18:7-16.
136. Derksen P., De Gorter D., Meijer H., Bende R., Van Dijk M., Lokhorst H., et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
137. Weimar I.S., de Jong D., Muller E.J., Nakamura T., van Gorp J.M.H.H., de Gast G.C., et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via α4β1 and α5β1 integrins. Blood 1997, 89:990-1000.
138. Mahtouk K., Tjin E.P.M., Spaargaren M., Pals S.T. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta (BBA)-Rev Cancer 2010, 1806:208-219.
139. Alexandrakis M., Passam F., Sfiridaki A., Kandidaki E., Roussou P., Kyriakou D. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003, 72:229-233.
140. Teofili L., Di Febo A.L., Pierconti F., Maggiano N., Bendandi M., Rutella S., et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001, 97:1063-1069.
141. Eksioglu-Demiralp E., Akdeniz T., Bayik M. Aberrant expression of c-met and HGF/c-met pathway provides survival advantage in B-chronic lymphocytic leukemia. Cytometry Part B: Clin Cytometry 2011, 80:1-7.
142. De Totero D., Giannoni P., Scaglione S., Quarto R., Narcisi R., Parodi M., et al. Chronic lymphocytic leukemic (CLL) B cells express the HGF receptor (c-MET) and are supported in their survival by HGF-producing mesenchymal stromal cells. Haematologica 2010, 95:316.
143. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem-Tokyo 2002, 132:359-400.
144. Kaname T., Kuwano A., Murano I., Uehara K., Muramatsu T., Kajii T. Midkine gene (MDK), a gene for prenatal differentiation and neuroregulation, maps to band 11p11. 2 by fluorescence in situ hybridization. Genomics 1993, 17:514-515.
145. Simon-Chazottes D., Matsubara S., Miyauchi T., Muramatsu T., Guénet J.L. Chromosomal localization of two cell surface-associated molecules of potential importance in development: midkine (Mdk) and basigin (Bsg). Mamm Genome 1992, 2:269-271.
146. Muramatsu T. The midkine family of growth/differentiation factors. Dev Growth Differ 1994, 36:1-8.
147. Tokuyama W., Mikami T., Fujiwara M., Matsui T., Okayasu I. Midkine expression in colorectal tumors: correlation with Ki-67 labeling in sporadic, but not ulcerative colitis-associated ones. Pathol Int 2007, 57:260-267.
148. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B 2010, 86:410-425.
149. Iwasaki W., Nagata K., Hatanaka H., Inui T., Kimura T., Muramatsu T., et al. Solution structure of midkine, a new heparin-binding growth factor. EMBO J 1997, 16:6936-6946.
150. Matsubara S., Take M., Pedraza C., Muramatsu T. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity. J Biochem 1994, 115:1088.
151. Reynolds P.R., Mucenski M.L., Le Cras T.D., Nichols W.C., Whitsett J.A. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem 2004, 279:37124-37132.
152. Tomomura M., Kadomatsu K., Matsubara S., Muramatsu T. A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. J Biol Chem 1990, 265:10765.
153. Nakanishi T., Kadomatsu K., Okamoto T., Ichihara-Tanaka K., Kojima T., Saito H., et al. Expression of syndecan-1 and-3 during embryogenesis of the central nervous system in relation to binding with midkine. J Biochem 1997, 121:197.
154. Maeda N.I.-T.K., Kimura T., Kadomatsu K., Muramatsu T., Noda M. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 1999, 274:12474-12479.
155. Muramatsu H., Zou K., Sakaguchi N., Ikematsu S., Sakuma S., Muramatsu T. LDL receptor-related protein as a component of the Midkine Receptor* 1. Biochem Biophys Res Commun 2000, 270:936-941.
156. Stoica G.E., Kuo A., Powers C., Bowden E.T., Sale E.B., Riegel A.T., et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002, 277:35990-35998.
157. Muramatsu H., Zou P., Suzuki H., Oda Y., Chen G.Y., Sakaguchi N., et al α4β1-and α6β1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 2004, 117:5405.
158. Take M., Tsutsui J., Obama H., Ozawa M., Nakayama T., Maruyama I., et al. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem 1994, 116:1063.
159. Shibata Y., Muramatsu T., Hirai M., Inui T., Kimura T., Saito H., et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002, 22:6788.
160. Ohuchida T., Okamoto K., Akahane K., Higure A., Todoroki H., Abe Y., et al. Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity. Cancer 2004, 100:2430-2436.
161. Xu Y., Qu X., Zhang X., Luo Y., Zhang Y., Luo Y., et al. Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett 2009, 279:137-144.
162. Kadomatsu K., Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004, 204:127-143.
163. Kaneda N., Talukder A.H., Nishiyama H., Koizumi S., Muramatsu T. Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro. J Biochem 1996, 119:1150-1156.
164. Hayashi K., Kadomatsu K., Muramatsu T. Requirement of chondroitin sulfate/dermatan sulfate recognition in midkine-dependent migration of macrophages. Glycoconj J 2001, 18:401-406.
165. Takada T., Toriyama K., Muramatsu H., Song X.J., Torii S., Muramatsu T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 1997, 122:453-458.
166. Sonobe Y., Li H., Jin S., Kishida S., Kadomatsu K., Takeuchi H., et al. Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells. J Immunol 2012, 188:2602-2611.
167. Krzystek-Korpacka M., Neubauer K., Matusiewicz M. Circulating midkine in Crohn's disease: clinical implications. Inflamm Bowel Dis 2010, 16:208-215.
168. Kosugi T., Yuzawa Y., Sato W., Arata-Kawai H., Suzuki N., Kato N., et al. Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy. Lab Invest 2007, 87:903-913.
169. Maruyama K., Muramatsu H., Ishiguro N., Muramatsu T. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004, 50:1420-1429.
170. Wang J., Takeuchi H., Sonobe Y., Jin S., Mizuno T., Miyakawa S., et al. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Nat Acad Sci 2008, 105:3915.
171. Weckbach L.T., Muramatsu T., Walzog B. Midkine in inflammation. TheScientificWorldJournal 2011, 11:2491.
172. Kato H, Watanabe K, Murari M, Isogai C, Kinoshita T, Nagai H, et al. Midkine expression in Reed-Sternberg cells of Hodgkin's disease. HARWOOD Academic Pub.; 2000. p 415-24.
173. Wang Y., Xing H., Tian Z., Tang K., Wang J., Xu Z., et al. Overexpression of Midkine promotes the viability of BA/F3 cells. Biochem Biophys Res Commun 2009, 384:341-346.
174. Cohen S., Shoshana O., Zelman-Toister E., Maharshak N., Binsky-Ehrenreich I., Gordin M., et al. The Cytokine Midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74. J Immunol 2012, 188:259-269.
175. Kadomatsu K. The Midkine family and its receptors. Exp Glycosci 2008:355-7.
176. Jono H., Ando Y. Midkine: a novel prognostic biomarker for cancer. Cancers 2010, 2:624-641.
177. Kadomatsu K., Hagihara M., Akhter S., Fan Q., Muramatsu H., Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997, 75:354.
178. Hidaka H., Yagasaki H., Takahashi Y., Hama A., Nishio N., Tanaka M., et al. Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia. Leuk Res 2007, 31:1045-1051.
179. Hu R., Yan Y., Li Q., Lin Y., Jin W., Li H., et al. Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol 2010, 92:105-110.
180. Ikematsu S., Yano A., Aridome K., Kikuchi M., Kumai H., Nagano H., et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000, 83:701.
181. Obata Y., Kikuchi S., Lin Y., Yagyu K., Muramatsu T., Kumai H. Serum midkine concentrations and gastric cancer. Cancer Sci 2005, 96:54-56.
182. Rawnaq T., Kunkel M., Bachmann K., Simon R., Zander H., Brandl S., et al. Serum Midkine correlates with tumor progression and Imatinib response in gastrointestinal stromal tumors. Ann Surg Oncol 2011, 18:559-565.
183. Shimada H., Nabeya Y., Okazumi S.I., Matsubara H., Kadomatsu K., Muramatsu T., et al. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. Oncol Rep 2003, 10:411-414.
184. Shimada H., Nabeya Y., Tagawa M., Okazumi S., Matsubara H., Kadomatsu K., et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003, 94:628-632.